The histological diagnosis was lymphocytic hypophysitis. Immunostains were positive for CD3 and CD20. Immunostains for acid-fast bacilli, PLAP and OCT3/4 were negative. The patient remains ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has ...

ICP-B02 binds to CD20 on the tumour cells and CD3 on the T cells, redirects and activates T cells to eradicate tumour cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...

Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s ...

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) has earned a consensus recommendation of “Reduce” from the ten analysts ...

establishing itself to the new standard of care and it's also an opportunity to further build upon it with combinations with the CD20/CD3 bispecifics that we have. Hemlibra patient share in the U ...

In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

ICP-B02 binds to CD20 on the tumor cells and CD3 on the T cells, redirects and activates T cells to eradicate tumor cells through T-cell Directed Cellular Cytotoxicity (TDCC), which has demonstrated ...